MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
19.90
-0.09 (-0.45%)
At close: Jun 26, 2026, 4:00 PM EDT
20.25
+0.35 (1.76%)
After-hours: Jun 26, 2026, 7:46 PM EDT
Company Description
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases.
It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis.
The company was founded in 2021 and is headquartered in Zug, Switzerland.
MoonLake Immunotherapeutics
| Country | Switzerland |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 130 |
| CEO | Jorge da Silva |
Contact Details
Address: Dorfstrasse 29 Zug, 6300 Switzerland | |
| Phone | 41 415108022 |
| Website | moonlaketx.com |
Stock Details
| Ticker Symbol | MLTX |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001821586 |
| CUSIP Number | 61559X104 |
| ISIN Number | KY61559X1045 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jorge Santos da Silva Ph.D. | Co-Founder, Interim Chair of the Board and Chief Executive Officer |
| Dr. Kristian Reich M.D., Ph.D. | Co-Founder and Chief Scientific Officer |
| Matthias Bodenstedt | Chief Financial Officer |
| Oliver Daltrop Ph.D. | Chief Technical Officer |
| Carla Bretes | Director of Investor Relations and External Communications |
| Nicolas Mosimann Ph.D. | General Counsel |
| Joana Cortez | Associate Vice-President of Legal and Compliance |
| Tino Anthamatten | Vice President of Marketing, Market Access and Pricing |
| Luciana Marques | Associate Vice-President of Human Resources, People and Culture |
| Nuala Brennan | Chief Clinical Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 25, 2026 | 8-K | Current Report |
| Jun 24, 2026 | 424B5 | Filing |
| Jun 22, 2026 | 424B5 | Filing |
| Jun 22, 2026 | 8-K | Current Report |
| Jun 15, 2026 | 144 | Filing |
| Jun 9, 2026 | 8-K | Current Report |
| Jun 1, 2026 | 8-K | Current Report |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 11, 2026 | 10-Q | Quarterly Report |
| May 11, 2026 | 8-K | Current Report |